高级检索

化浊通清饮治疗慢性萎缩性胃炎浊毒内蕴证的临床疗效观察

Clinical efficacy of Huazhuo Tongqing Decoction in treating chronic atrophic gastritis with internal accumulation of turbidity and poison

    摘要
  • 摘要:
    目的 探讨化浊通清饮对慢性萎缩性胃炎（CAG）浊毒内蕴证的临床疗效。
    方法 将159例CAG患者随机分为中药组、西药组和对照组，分别给予化浊通清饮、雷贝拉唑钠肠溶片和摩罗丹治疗。比较西医临床疗效、中医证候评分、病理改变、简明健康状况调查量表（SF-36）评分及治疗前后血清胃泌素-17（G-17）和前列腺素E2（PGE2）水平。
    结果 中药组治疗总有效率为92.45 %，西药组为62.26 %，对照组为66.04 %。与治疗前比较，3组治疗后腺体萎缩、肠上皮化生、异型增生、慢性炎症评分降低，且中药组上述评分低于对照组和西药组，差异有统计学意义（P < 0.05）。治疗3个月后，3组胃脘疼痛、胃胀不舒、反酸烧心、嗳气、便黏评分均低于治疗前，且中药组胃脘疼痛、胃胀不舒、反酸烧心、嗳气、便黏评分低于对照组和西药组，差异有统计学意义（P < 0.05）。3组患者治疗后1、2、3个月SF-36评分均提高，且中药组SF-36评分高于对照组和西药组，随访时中药组SF-36评分仍高于对照组和西药组，差异有统计学意义（P < 0.05）。治疗后，3组患者血清G-17和PGE2水平均较治疗前升高，且中药组血清G-17和PGE2水平高于西药组和对照组，差异有统计学意义（P < 0.05）。3组患者治疗期间均无不良反应发生。
    结论 化浊通清饮治疗CAG能减轻患者症状，改善病理状态，提升患者生活质量。

     

    Abstract:
    Objective To explore the clinical effect of Huazhuo Tongqing Yin in treating chronic atrophic gastritis (CAG) with internal accumulation of turbidity and poison.
    Methods A total of 159 patients with CAG were randomly divided into traditional Chinese medicine group, western medicine group and control group, and were given Huazhuo Tongqing Decoction, rabeprazole sodium enteric-coated tablets and morodan, respectively. Clinical efficacy, TCM syndromes, pathological changes, 36-item Short-form Health Status Survey(SF-36) score and serum gastrin-17 (G-17) and prostaglandin E2 (PGE2) before and after treatment were compared.
    Results The total effective rate was 92.45% in Chinese medicine group, 62.26% in western medicine group and 66.04% in control group. After three months of treatment, the scores of epigastric pain, gastric distension and discomfort, acid regurgitation and heartburn, belching, and stool stickiness in the three groups were all lower than those before treatment, and the scores of epigastric pain, gastric distension and discomfort, acid regurgitation and heartburn, belching, and sticky stool in the traditional Chinese medicine group were lower than those in the control group andthe western medicine group (P < 0.05). The SF-36 scores of the three groups at 1-, 2-, 3-month improved after treatment, and the SF-36 score of the traditional Chinese medicine group was higher than that of the control group and the western medicine group (P < 0.05). During follow-up, the SF-36 score of the traditional Chinese medicine group was still higher than those of the control group and the western medicine group (P < 0.05). After treatment, the serum levels of G-17 and PGE2 in the three groups were higher thanthose before treatment, and were higher in the traditional Chinese medicine group than those in the western medicine group and the control group (P < 0.05). No adverse reactions occurred in any of the three groups during treatment.
    Conclusion Huazhuo Tongqing Decoction can alleviate the symptoms of CAG, improve the pathological state and the quality of life.

     

    • HTML全文
    • 参考文献(19)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回